Summary
Recombinant DNA technology allows the production of insulin analogues with faster absorption rates from subcutaneous tissue as compared to soluble human insulin. The human insulin analogue B10Asp (mono/dimeric) is absorbed twice as fast as soluble human insulin (hexameric). A double blind, randomised crossover study with a 1-month run-in period and two 2-month treatment periods was performed in 21 male insulin-dependent diabetic (IDDM) patients aged 18–40 years in order to compare the metabolic control obtained with equimolar doses of the analogue B10Asp vs soluble human insulin (Actrapid) given as mealtime insulin and intermediate acting isophane insulin (Protaphane) at bedtime. At the end of each 2-month study period, the patients were admitted to the metabolic ward. We found significantly higher plasma insulin/analogue levels after breakfast, lunch and dinner with B10Asp as compared to Actrapid (p<0.05). The plasma insulin/analogue levels were significantly lower before lunch and dinner with B10Asp as compared to Actrapid (p<0.05). Also, the plasma insulin/analogue level tended to be lower at bedtime when comparing B10Asp to Actrapid. The 24-h blood glucose profiles showed identical fasting blood glucose, significantly lower blood glucose after breakfast with the analogue (p<0.05), no differences in blood glucose after lunch and dinner but a significantly higher blood glucose at midnight using the analogue (p<0.05). The overall 24-h mean blood glucose concentrations, the daily insulin dose, HbA1c, diet, home blood glucose monitoring and frequency of hypoglycaemia were almost identical in the two treatment periods. In conclusion, the overall glycaemic control remained unchanged and quite good when Actrapid was exchanged dose for dose with the insulin analogue B10Asp in IDDM patients treated with a basal bolus regime.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Abbreviations
- IDDM:
-
Insulin-dependent diabetes mellitus
- RIA:
-
radioimmunoassay
- IGF-I:
-
insulin-like growth factor-I
References
Eschewege E, Job D, Guyot-Argenton C, Aubry JP, Tchobroutsky G (1979) Delayed progression of diabetic retinopathy by divided insulin administration: a further follow up. Diabetologia 16: 13–15
Deckert T, Lauritzen T, Parving H-H, Christiansen JS (1984) Effect of two years of strict metabolic function in long-term insulin-dependent diabetes. Diabetic Nephropathy 3: 6–10
The Kroc Collaborative Study Group (1984) Blood glucose control and the evolution of diabetic retinopathy and albuminuria. N Engl J Med 311: 365–372
Beck-Nielsen H, Richelsen B, Mogensen CE (1985) Effect of insulin pump treatment for one year on renal function and retinal morphology in patients with IDDM. Diabetes Care 8: 585–589
Olsen T, Richelsen B, Ehlers N, Beck-Nielsen H (1987) Diabetic retinopathy after 3 years treatment with continous subcutaneous insulin infusion (CSII). Acta Ophtalmol 65: 185–189
Christensen CK, Sandahl Christiansen J, Schmidt A (1987) Effect of continuous subcutaneous insulin infusion on kidney function and size in IDDM patients: a 2-year controlled study. J Diab Compl 1: 91–95
Dahl-JØrgensen J, Hanssen KF, Kierulf P, BjØro T, Sandvik L, Aagenaes Ø (1988) Reduction of urinary albumin excretion after 4 years of continuous subcutaneous insulin infusion in insulin-dependent diabetes mellitus. Acta Endocrinol 117: 19–25
Verrillo A, de Teresa A, Martino C, Verrillo L, di Chiara G (1988) Long-term correction of hyperglycemia and progression of retinopathy in insulin dependent diabetes: a five-year randomized prospective study. Diabetes Research 8: 71–76
Reichard P, Berglund B, Britz A, Cars I, Nilsson BY, Rosenqvist U (1991) Intensified conventional insulin treatment retards the microvascular complications of insulin-dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. J Intern Med 230: 101–108
Wang PH, Lau J, Chalmers TC (1993) Meta-analysis of effects of intensive blood-glucose control on late complications of type 1 diabetes. Lancet 341: 1306–1309
The Diabetes Contact and Complication Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 329: 977–986
Small M, MacRury S, Boal A, Paterson KR, MacCuish AC (1988) Comparison of conventional twice daily subcutaneous insulin administration and a multiple injection regimen (using the NovoPenℳ) in insulin-dependent diabetes mellitus. Diabetes Research 8: 85–89
Gall M-A, Mathiesen ER, SkØtt P, Musaeus L, Damm S, Beck-Nielsen H et al. (1989) Effect of multiple insulin injections with a pen injector on metabolic control and general well-being in insulin-dependent diabetes mellitus. Diabetes Research 11: 97–101
Houtzagers CMG, Berntzen PA, van der Stap H et al. (1989) Efficacy and acceptance of two intensified conventional insulin therapy regimens: a long-term cross-over comparison. Diabet Med 6: 416–421
Eaton RP, Allen RC, Schade S, Standefer JC (1980) Normal insulin secretion: the goal of artificial insulin delivery systems? Diabetes Care 3: 270–273
Schade DS, Eaton RP, Spencer W (1980) Normalisation of plasma insulin in diabetic subjects with programmed insulin delivery. Diabetes Care 3: 9–14
Owens DR (1986) Human insulin: clinical pharmacological studies in normal man. MTP Press Lancaster pp. 46–70
Van Haeften TW, Bolli GB, Dimitridias GD, Gottesman IS, Horwitz DL, Gerich JE (1986) Effect of insulin antibodies and their kinetic characteristics on plasma free insulin dynamics in patients with diabetes mellitus. Metabolism 7: 649–656
Home PD, Pickup JC, Keen H, Alberti KGMM, Parson JA, Binder C (1981) Continuous subcutaneous insulin infusion: comparison of plasma insulin profiles after infusion or bolus injection of the mealtime dose. Metabolism 30: 439–442
Blundell T, Dodson G, Hodgkin D, Mercola D (1972) Insulin: the structure in the crystal and its reflection in chemistry and biology. Adv Protein Chem 26: 279–402
Binder C (1969) Absorption of injected insulin. Acta Pharmacol Toxicol 17: 67–87
Mosekilde E, Jensen KS, Binder C, Pramming S, Thorsteinsson B (1989) Modeling absorbtion kinetics of subcutaneous injected soluble insulin. J Pharmacokinet Biopharm 17: 67–87
Brange J, Ribel U, Hansen JF et al. (1988) Monomeric insulins obtained by protein engineering and their medical implications. Nature 333: 679–682
Kang S, Brange J, Burch A, VØlund A, Owens DR (1991) Subcutaneous insulin absorption explained by insulin's physicochemical properties. Evidence from absorption studies of soluble human insulin and insulin analogues in humans. Diabetes Care 14: 942–948
Kang S, Creagh FM, Peters JR, Brange J, VØlund A, Owens DR (1991) Comparison of subcutaneous soluble human insulin and insulin analogues (AspB9, GluB27; AspB10; AspB28) on meal-related plasma glucose excursions in type I diabetic subjects. Diabetes Care 14: 571–577
Heinemann L, Starke AA, Heding L, Jensen I, Berger M (1990) Action profiles of fast onset insulin analogues. Diabetologia 33: 384–386
Hother-Nielsen O, Faber O, SØrensen NS, Beck-Nielsen H (1988) Classification of newly diagnosed diabetic patients as insulin-requiring or non-insulin-requiring based on clinical and biochemical variables. Diabetes Care 11: 531–537
Andersen I, Hannibal S (1983) Analytical and economical optimization of a glucose method with immobilized enzymes. J Automatic Chemistry 4: 188–192
Goldstein DE, Peth SB, England JD, Hess RL, Randall LH, DaCosta J (1980) Effects of acute changes in blood glucose on HbA1c. Diabetes 29: 623–628
Heding LG (1972) Determination of total serum (IRI) in insulin-treated diabetic patients. Diabetologia 8: 260–266
Schlichtkrull J, Munch O, Jersild M (1965) The M-value, an index of blood sugar in diabetes. Acta Med Scand 177: 95–102
Friedewald WT, Levy RI, Frederickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifugation. Clin Chem 18: 499–502
Christensen C, Ørskov C (1984) Rapid screening PEG radioimmunoassay for quantification of pathological microalbuminuria. Diabetic Nephropathy 3: 92–94
Drejer K, Kruse V, Larsen UD (1988) Insulin analogs: binding to the human liver cell line, Hep G2. Diabetes Res Clin Pract 5 [Suppl 2]: 102–103 (Abstract)
Jansson PA, Fowelin JP, von Schenck HP, Smith UP, Lönnroth PN (1993) Measurement by microdialysis of the insulin concentration in subcutaneous interstitial fluid. Diabetes 42: 1469–1473
JØrgensen LN, Nielsen FS (1990) Timing of pre-meal insulins in diabetic patients on a multiple daily injection regimen. A questionnaire study. Diabetologia 33: A116 (Abstract)
Linde B (1986) Dissociation of insulin absorption and blood flow during massage of a subcutaneous injection site. Diabetes Care 6: 570–574
Dillon RS (1983) Improved serum insulin profiles in diabetic individuals who massaged their insulin injection sites. Diabetes Care 6: 399–401
Taylor R, Home PD, Alberti KGMM (1981) Plasma free insulin profiles after administration of insulin by jet and conventional syringe injections. Diabetes Care 4: 377–379
Pehling GB, Gerlich JE (1984) Comparison of plasma insulin profiles after administration of insulin by jet spray and conventional needle in patients with insulin-dependent diabetes mellitus. Mayo Clin Proc 59: 751–754
Edsberg B, Herly D, Hildebrandt P, Kühl C (1987) Insulin bolus given by sprinkler needle: effect on absorption and glycaemic responce to a meal. BMJ 294: 1373–1376
Linde B, Gunnarsson R (1985) Influence of aprotinin on insulin absorption and subcutaneous blood flow in type 1 (insulin-dependent) diabetes. Diabetologia 28: 645–648
Kang S, Brange J, Burch A, VØlund A, Owens DR (1991) Absorption kinetics and action profiles of subcutaneously administered insulin analogues (AspB9, GluB27, AspB10, AspB28) in healthy subjects. Diabetes Care 14: 1057–1065
JØrgensen LN, Didriksen LH, Drejer K (1992) Carcinogen effect of the human insulin analogue B10 Asp in female rats. Diabetologia 35 [Suppl 1]: A3 (Abstract)
Bornfeldt KE, Gidlof RA, Wasteson A, Lake M, Skottner A, Arnqvist HJ (1991) Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cell. Comparison of maximal growth promoting activities. Diabetologia [Suppl] 34: 307–313
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nielsen, F.S., JØrgensen, L.N., Ipsen, M. et al. Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen. Diabetologia 38, 592–598 (1995). https://doi.org/10.1007/BF00400729
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00400729